Published in Targetome · View the paper (DOI)
The mbLFIA platform overcomes the sensitivity bottleneck in traditional enzyme-free isothermal amplification approaches by using dual-mechanism multisite bridging and gold-platinum nanoparticles. It achieved a visual limit of detection as low as 2 pmol·L⁻¹ for CHIKV, demonstrating perfect clinical sensitivity and specificity.
Coverage from 2 institutions